Callaghan, CJ; Charman, SC; Muiesan, P; Powell, JJ; Gimson, AE; van der Meulen, JH; UK Liver Transplant Audit, (2013) Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study. BMJ open, 3 (9). e003287. ISSN 2044-6055 DOI: https://doi.org/10.1136/bmjopen-2013-003287

Downloaded from: http://researchonline.lshtm.ac.uk/1229618/

DOI: 10.1136/bmjopen-2013-003287
Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study

Christopher J Callaghan,1 Susan C Charman,2,3 Paolo Muiesan,4 James J Powell,5 Alexander E Gimson,1 Jan H P van der Meulen,2,3 on behalf of the UK Liver Transplant Audit

ABSTRACT

Objectives: Outcomes of liver transplantation from donation after circulatory death (DCD) donors may be inferior to those achieved with donation after brain death (DBD) donors. The impact of using DCD donors is likely to depend on specific national practices. We compared risk-adjusted graft loss and recipient mortality after transplantation of DCD and DBD livers in the UK.

Design: Prospective cohort study. Multivariable Cox regression and propensity score matching were used to estimate risk-adjusted HR.

Setting: 7 liver transplant centres in the National Health Service (NHS) hospitals in England and Scotland.

Participants: Adults who received a first elective liver transplant between January 2005 and December 2010 who were identified in the UK Liver Transplant Audit.

Interventions: Transplantation of DCD and DBD livers.

Outcomes: Graft loss and recipient mortality.

Results: In total, 2572 liver transplants were identified with 352 (14%) from DCD donors. 3-year graft loss (95% CI) was higher with DCD livers (27.3%, 21.8% to 33.9%) than with DBD livers (18.2%, 16.4% to 20.2%). After adjustment with regression, HR for graft loss was 2.3 (1.7 to 3.0). Similarly, 3-year mortality was higher with DCD livers (19.4%, 14.5% to 25.6%) than with DBD livers (14.1%, 12.5% to 16.0%) with an adjusted HR of 2.0 (1.4 to 2.8). Propensity score matching gave similar results. Centre-specific adjusted HRs for graft loss and recipient mortality seemed to differ among transplant centres, although statistical evidence is weak (p value for interaction 0.08 and 0.24, respectively).

Conclusions: Graft loss and recipient mortality were about twice as high with DCD livers as with DBD livers in the UK. Outcomes after DCD liver transplantation may vary between centres. These results should inform policies for the use of DCD livers.

INTRODUCTION

The increasing disparity between the demand and supply of donor livers is a major challenge. The need to increase the donor pool, and improve organ utilisation, has led to the reintroduction and rapid expansion of the use of livers from donation after circulatory death (DCD) donors. These donors have been classified as either uncontrolled, where cardiac arrest has occurred unexpectedly (Maastricht categories I and II), or controlled, where potential donors have life-sustaining treatment withdrawn after further interventions are deemed futile (Maastricht III), or circulatory...
death occurs in a donation after brain death (DBD) donor (Maastricht IV).\textsuperscript{1}

Unlike DBD donors, livers from DCD donors undergo a variable period of warm ischaemia, during which time irreversible cellular damage may occur. Reliably measuring the warm ischaemic period is difficult outside of hospital, which means that the use of livers from uncontrolled DCD donors is limited.\textsuperscript{2} In contrast, planned withdrawal of life-sustaining treatment in Maastricht III donors enables close cardiorespiratory monitoring, provision of a prepared procurement team and minimisation of subsequent warm ischaemia. As such, the use of livers from controlled DCD donors has risen dramatically in the USA\textsuperscript{3} and Europe.\textsuperscript{4}

US registry analyses have demonstrated that DCD liver transplantation has worse graft and patient survival than DBD liver transplantation.\textsuperscript{5–8} This is thought to be predominantly due to a higher rate of biliary complications in DCD livers than other causes of graft loss.\textsuperscript{9} Recognition of these issues has perhaps contributed to a recent drop in the number of DCD livers transplanted in the USA.\textsuperscript{3,10} However, as a result of encouraging early reports\textsuperscript{11,12} and decreasing DBD liver transplantation rates, the use of DCD livers in the UK is now more widespread than in the USA.

As there are differences between UK and US practice with respect to how DCD livers are being used,\textsuperscript{13,14} we report in this article graft loss and recipient mortality after transplantation of DCD and DBD livers in the UK. Two risk-adjustment techniques were used to control for differences in donor and recipient risk factors.

**MATERIALS AND METHODS**

**Inclusion criteria**

Using data submitted to the UK Liver Transplant Audit,\textsuperscript{15} we identified all adult patients (aged >16 years) receiving a first liver transplant in the seven UK transplant centres between 1 January 2005 and 31 December 2010. Follow-up ceased on 31 March 2011. Regular checks indicate that data are consistently more than 93% complete and accurate.\textsuperscript{16–18} Patients receiving living or domino donors were excluded, as were those having an emergency (‘super urgent’\textsuperscript{19}) or multiorgan transplant. We are not aware of any uncontrolled DCD liver transplants having been performed in the UK during the study period.

**Donor and recipient selection and organ procurement**

Criteria for DCD donor selection and acceptable post-withdrawal haemodynamic parameters varied among the liver transplant centres, but were broadly based on the experience of Muiesan et al,\textsuperscript{12} and in line with US guidelines.\textsuperscript{19} Administration of heparin or vasodilators, or pre-dissection of femoral vessels before death, is prohibited by law in the UK. Death was declared after cardiorespiratory arrest with a minimum interval of 5 min. All UK liver procurement centres used a super-rapid recovery technique,\textsuperscript{19} although preservation fluid type, bag pressure and the use of dual perfusion techniques varied.

Livers from DCD and DBD donors were allocated locally, and centres chose recipients according to local criteria.\textsuperscript{20} Optimal livers from DBD donors were offered to paediatric centres for splitting and implantation of the left lateral segment, with implantation of the extended right lobe into an adult recipient.

**Statistical analyses**

Pearson’s $\chi^2$ test was used to identify differences of categorical variables and Student’s t test or Mann-Whitney test for differences of continuous variables. Graft and recipient survival after transplantation were estimated using Kaplan-Meier methods. Graft loss was defined as retransplantation or death, regardless of perceived graft function at the time of death. Cold ischaemic time (CIT) was defined as the duration from the start of cold perfusion of the liver in the donor to organ removal from ice immediately prior to implantation.

A multivariable Cox regression model was used to adjust the comparisons of graft loss and recipient mortality between DCD and DBD livers for differences in risk factors at the time of transplantation. The donor, recipient and operative characteristics presented in tables 1 and 2 were included in the model. UK End-Stage Liver Disease (UKELD) and Model for End-Stage Liver Disease (MELD) scores were calculated for recipients,\textsuperscript{21,22} but these scores were not incorporated in the multivariable model as the component variables of both were already included.

To test whether the impact of using DCD livers on graft loss and patient mortality varied among UK transplant centres, we included an interaction term of donor type and centre in the Cox model. The likelihood ratio test was used to test the statistical significance of the risk factors. The results of the survival analyses are presented as HR with 95% CI.

An analysis with propensity score matching was also conducted. The propensity score is the probability that a recipient would have received a liver from a DCD (as opposed to DBD) donor, based on observed donor and recipient characteristics. A logistic regression model was used to generate the propensity score.\textsuperscript{23} Donor type was regressed on main effects only and donor, recipient and operative characteristics were selected using a stepwise process with conservative removal (p>0.20) and entry criteria (p<0.10). We considered all two-way interactions of the main effects and explored non-linear relationships by including quadratic terms of continuous model factors. All interactions and quadratic terms with a p value <0.05 were selected. We estimated the propensity score based on the logistic regression model as the sum of the products of the model factors and their coefficients. Then, for each recipient in the DCD group we selected an individual from the DBD group by matching on the log of the estimated propensity score, using a nearest-neighbour matching algorithm with callipers (an interval) of maximum width of 0.2 SDs. We compared the...
distribution of all model factors in the DCD and DBD groups to assess the success of the propensity score model. The above processes were repeated for each of the 10 imputed data sets (see below for a description of methods to deal with missing data). The balance in the covariates across the treatment groups was considered to be achieved if the standardised differences were less than 10%.24 Cox regression was then performed on each of the 10 sets of matched pairs to estimate the effect of donor type on patient and graft survival. A robust SE was used to allow for the clustering on the pairs. The estimates were then combined using Rubin’s rules to provide adjusted HRs and their 95% CI.

In addition to the donor, recipient and operative characteristics presented in tables 1 and 2, we also considered the following characteristics as candidates for inclusion in the propensity score model (all are yes/no unless otherwise stated): lifestyle activity score on five-point scale, liver failure grade (acute/not acute), encephalopathy grade on five-point scale, oesophageal varices, diuretic therapy, fever, sepsis, haemoglobin, white cell count, platelet count, serum urea, anticytomegalovirus status and antihepatitis C virus status. Types of biliary and hepatic arterial anastomoses were also considered as was the use of antifibrinolytic therapy.

**Missing values**

All model factors had missing values for less than 5% of patients with the exception of donor history of diabetes (7%) and donor organ appearance (19%). Multiple imputation using chained equations was used to fill in missing values. The imputation model included the model factors above, type of donor as well as terms representing the outcome (log of survival time and the censoring indicator).25 We created 10 imputed data sets, and the model parameters based on these data sets were combined using Rubin’s rules.

**RESULTS**

We identified 2572 first elective adult liver transplants. Of these, 352 (14%) had a graft from a DCD donor. Use of livers from DCD donors progressively increased from 6.9% in 2005 to 26.3% in 2010, an almost four-fold rise over that time period. Two centres used DCD donor livers in more than 30% of first elective adult liver transplants in 2010.

**Donor, recipient and operative characteristics**

Compared to DBD liver donors, DCD donors were younger, had lower body mass indices, lower serum sodium concentrations and were more likely to be men (table 1). Although a similar proportion of organs appeared normal in the two groups, DCD donors had a higher proportion of missing values (29%) than DBD donors (18%). The cause of death for DBD donors was predominantly stroke (70%), whereas the corresponding proportion in the DCD group was 49%. Trauma was more common in DCD donors (23%) than in DBD donors (11%). In 352 DCD donors, the median (IQR) time from withdrawal of life support to cardiac arrest was 15 (11–20) min, whereas the median duration from cardiac arrest to cold perfusion was 12 (9–14) min.

Recipients of a DCD liver were more likely to be older, men, have lower serum bilirubin concentration and cancer as the primary liver disease (table 2). Both UKELD and MELD scores were lower in recipients of DCD livers, most probably because a higher proportion of DCD recipients had cancer as their primary disease. DCD livers were more likely to be used as whole rather than partial grafts. Median graft CIT was significantly lower for DCD donors and there were more ethnicity mismatches in this group.

**Graft and patient survival**

Graft loss was higher in DCD recipients (figure 1), with a 3-year graft loss (95% CI) of 27.3% (21.8 to 33.9) for
DCD recipients and 18.2% (16.4 to 20.2) for DBD recipients with an unadjusted HR of 1.6 (1.2 to 2.0; table 3). Recipient mortality was also increased with DCD livers (figure 1). Three-year mortality was 14.1% (12.5 to 16.0) for DBD recipients and 19.4% (14.5 to 25.6) for DCD recipients with an unadjusted mortality HR of 1.4 (1.1 to 2.0) for use of a DCD donor liver.

After adjustment using the multivariable Cox regression model, we found that the risk of graft loss within 3 years of transplantation in recipients of a DCD donor liver was more than twice that of those receiving a DBD liver: adjusted HR 2.3 (1.7 to 3.0). Adjusted 3-year patient mortality was also significantly higher in recipients of livers from DCD donors: adjusted HR 2.0 (1.4 to 2.8; table 3).

After adjustment using the propensity score analysis, use of a liver from a DCD donor was associated with an adjusted HR of 2.3 (1.3 to 4.1) for graft loss. The adjusted HR for recipient mortality was 2.0 (1.0 to 4.2; table 3).

**Centre-specific estimates of DCD risk**

Although the interaction between donor type and centre was not statistically significant for either graft loss

---

**Table 2  Recipient and operative characteristics by donor type**

<table>
<thead>
<tr>
<th>Liver donor type</th>
<th>Recipient and operative characteristics</th>
<th>DCD (n=352)</th>
<th>DBD (n=2220)</th>
<th>p Value</th>
<th>Missing (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age, years</td>
<td>53 (9)</td>
<td>52 (11)</td>
<td>0.02</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Male sex</td>
<td>247 (70)</td>
<td>1436 (65)</td>
<td>0.04</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>BMI, kg/m²</td>
<td>27 (5)</td>
<td>27 (6)</td>
<td>0.94</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Serum sodium, mmol/L</td>
<td>137 (134–140)</td>
<td>137 (134–140)</td>
<td>0.38</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Serum potassium, mmol/L</td>
<td>4.2 (0.5)</td>
<td>4.2 (0.5)</td>
<td>0.23</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Serum creatine, μmol/L</td>
<td>89 (72–109)</td>
<td>86 (72–104)</td>
<td>0.92</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Serum albumin, g/L</td>
<td>32 (29–37)</td>
<td>32 (27–36)</td>
<td>0.40</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Serum bilirubin, mmol/L</td>
<td>41 (21–79)</td>
<td>47 (24–100)</td>
<td>&lt;0.01</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>INR</td>
<td>1.4 (1.2–1.6)</td>
<td>1.4 (1.2–1.6)</td>
<td>0.90</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>UKELD score</td>
<td>54 (50–57)</td>
<td>55 (51–59)</td>
<td>&lt;0.01</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>MELD score</td>
<td>15 (11–19)</td>
<td>15 (12–20)</td>
<td>0.04</td>
<td>57</td>
</tr>
<tr>
<td>Primary liver disease</td>
<td>Cancer</td>
<td>118 (33)</td>
<td>461 (21)</td>
<td>&lt;0.01</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>HCV</td>
<td>47 (13)</td>
<td>265 (12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC</td>
<td>23 (7)</td>
<td>233 (10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HBV</td>
<td>6 (2)</td>
<td>52 (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBC</td>
<td>34 (10)</td>
<td>238 (11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALD</td>
<td>71 (20)</td>
<td>516 (23)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AID</td>
<td>22 (6)</td>
<td>193 (9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metabolic</td>
<td>15 (4)</td>
<td>86 (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>16 (5)</td>
<td>176 (8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inpatient and ventilatory status</td>
<td>No</td>
<td>315 (90)</td>
<td>1931 (87)</td>
<td>0.15</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Inpatient, not ventilated</td>
<td>36 (10)</td>
<td>322 (14)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ventilated</td>
<td>3 (1)</td>
<td>21 (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days in intensive care</td>
<td>No</td>
<td>2 (1, 4)</td>
<td>2 (1, 4)</td>
<td>0.38</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Preoperative renal support</td>
<td>333 (95)</td>
<td>2116 (96)</td>
<td>0.71</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>18 (5)</td>
<td>98 (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organ type</td>
<td>Whole</td>
<td>343 (97)</td>
<td>1956 (88)</td>
<td>&lt;0.01</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Partial</td>
<td>9 (3)</td>
<td>263 (12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cold ischaemic time, h</td>
<td>No</td>
<td>6.7 (5.6–8.0)</td>
<td>9.5 (7.8–11.1)</td>
<td>&lt;0.01</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>Anastomosis time, min</td>
<td>41 (35–50)</td>
<td>42 (36–51)</td>
<td>0.42</td>
<td>90</td>
</tr>
<tr>
<td>Ethnicity mismatch</td>
<td>No</td>
<td>272 (77)</td>
<td>1868 (84)</td>
<td>&lt;0.01</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>79 (22)</td>
<td>343 (15)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values are numbers (percentages) for categorical variables and means (SDs) or median (IQR) otherwise.

AID, autoimmune disease; ALD, alcoholic liver disease; BMI, body mass index; DBD, donation after brain death; DCD, donation after circulatory death; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalised ratio; MELD, Model for End-Stage Liver Disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; UKELD, UK End-Stage Liver Disease.
or recipient mortality (p=0.24), the relative impact of using DCD livers on graft loss and recipient mortality seemed to vary among the seven transplant centres. Centre-specific adjusted HRs for graft loss and recipient mortality varied from being smaller than 1 to larger than 4 (figure 2).

Table 3  Recipient 3-year graft loss and mortality by donor type

<table>
<thead>
<tr>
<th>Liver donor type</th>
<th>Unadjusted HR (95% CI)</th>
<th>Adjusted HR (95% CI) Multivariable model</th>
<th>Adjusted HR (95% CI) Propensity score analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Three-year graft loss percentage (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donation after circulatory death</td>
<td>27.3 (21.8 to 33.9)</td>
<td>1.6 (1.2 to 2.0)</td>
<td>2.3 (1.7 to 3.0)</td>
</tr>
<tr>
<td>Donation after brain death</td>
<td>18.2 (16.4 to 20.2)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Three-year mortality percentage (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donation after circulatory death</td>
<td>19.4 (14.5 to 25.6)</td>
<td>1.4 (1.1 to 2.0)</td>
<td>2.0 (1.4 to 2.8)</td>
</tr>
<tr>
<td>Donation after brain death</td>
<td>14.1 (12.5 to 16.0)</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

HRs are unadjusted or adjusted based on either a multivariable Cox regression model or propensity score matching.

Figure 1  Graft survival after first elective adult liver transplantation using livers from donation after circulatory death (DCD) donors and donation after brain death (DBD) donors.
Causes of graft loss
When causes of graft loss were analysed over 3-year post-transplantation, the rates of biliary causes of graft loss were higher in livers from DCD donors (4/72 (6%)) than DBD donors (4/330 (1%); p=0.04). Rates of biliary stricture requiring intervention were very similar between the two groups (DCD donors 13/347 (4%) vs DBD donors 81/2193 (4%; p=0.96)).

DISCUSSION
Recipients of DCD livers, after risk adjustment, have approximately twice the risk of graft loss and death within 3 years of transplantation than recipients of livers from DBD donors. This is the first study that has analysed risk-adjusted outcomes in recipients of livers from DCD donors outside of the USA. Although US-based studies have reported on larger numbers of DCD liver transplant recipients, rates of DCD liver usage in the UK are more than double that of the USA.6 7 8

Our results are in contrast with single-centre reports that demonstrate good short-term results with liver transplantation from DCD donors,12 26 with graft loss and patient mortality similar to those from DBD donors.27 29 However, it is important to note that we found that the impact of using DCD livers on graft loss and recipient mortality seemed to differ among the seven UK transplant centres, although these differences did not reach statistical significance. This finding indicates that it is important to investigate centre-specific practices that may impact on the outcomes of transplantation of DCD livers, including the selection of DCD grafts, definition of warm ischaemic limits and procurement and implantation techniques.

Risk factors for graft loss and patient mortality are unevenly distributed between DBD and DCD donors and recipients. For example, partial organs were more often used for DBD recipients than for DCD recipients. However, risk adjustment or matching techniques are therefore crucial for a valid comparison of outcomes. Because estimates from multivariable models can be less robust when many factors are included, we also used propensity score matching. Reassuringly, both risk-adjustment required into the impact of procurement techniques and implantation centres.

In the UK, DCD liver donors are marginally older and have longer times from withdrawal of life-sustaining treatment to cold perfusion than in the USA.6 7 9 13 14 31 These differences are likely to reflect a wider acceptance of transplantation of DCD livers in the UK than in the USA and that treatment withdrawal in the UK takes place in the intensive care unit or the anaesthetic room rather than cardiac arrest or cold perfusion.8 37 National prospective data collection of postwithdrawal cardiorespiratory parameters in Maastricht III DCD donors has therefore been initiated in both the UK and the USA.8 Further research is also required into the impact of procurement techniques and preservation fluids on graft function,38 and the emerging role of machine perfusion.29

The allocation of deceased donor livers in the UK is currently on a local basis, with national organ sharing only for those patients with acute liver failure reaching specific criteria.39 Although local allocation reduces CIT, which is an important risk factor for graft survival, the current system raises issues of equity of access to a national resource. The ultimate aim of our analyses of national registry data is to inform discussions on how best to utilise this resource.40 For example, one could use our results as further support for not using livers from DCD donors for patients with a low risk of death on the waiting list as these recipients are able to wait for a graft that is more likely to have a favourable long-term outcome. An exception could be made for patients with

hepatocellular carcinoma. Although, these patients generally have low UKELD scores—indicating a low risk of mortality on the waiting list—they have a high risk of disease progression, which is an additional argument to use livers from DCD donors for this group.

The relative benefit associated with transplantation of a DCD versus a DBD donor liver is expected to be dependent not only on donor and recipient factors, but also on the overall availability of donor livers within each region or country, the rate of deaths on the waiting list and the impact of DCD transplantation on the subsequent need for retransplantation. Allocation policies also need to determine whether DCD organs are to be distributed on the basis of utility, urgency or overall survival benefit. Although livers transplanted from DCD donors have inferior outcomes to those from DBD donors, they remain a valuable additional source of grafts, especially in countries with relatively low rates of DBD organ donation.

Acknowledgements The authors would like to thank all the seven UK liver transplant centres for providing data to the UK Liver Transplant Audit and all those involved in collecting and handling liver transplant data at the National Health Service (NHS) Blood and Transplant authority, and Kerri Barber, lead liver transplant statistician at the authority.

Contributors CJC, AEG, SCC and JHPVDM designed the study. SCC analysed the data. All authors contributed to the interpretation of the results. CJC wrote the first draft of the manuscript supported by SCC and JHPVDM. All authors commented on later drafts of the manuscript. JHPVDM is the guarantor.

Funding NHS National Specialised Commissioning Group.

Competing interests None.
REFERENCES

Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study

Christopher J Callaghan, Susan C Charman, Paolo Muiesan, et al.

BMJ Open 2013 3:
doi: 10.1136/bmjopen-2013-003287

Updated information and services can be found at:
http://bmjopen.bmj.com/content/3/9/e003287.full.html

These include:

References
This article cites 40 articles, 1 of which can be accessed free at:
http://bmjopen.bmj.com/content/3/9/e003287.full.html#ref-list-1

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Gastroenterology and hepatology (69 articles)
Health services research (364 articles)
Surgery (100 articles)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/